ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached $250.9M in cash as of December 31, 2024 , provides runway expected to fund operations into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024 , and provided recent operational updates. "We achieved several key milestones in 2024, advancing our expansion tr
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR Newswire
- ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Newron Presents 2024 Financial Results and Provides 2025 Outlook [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferencePR Newswire
- ADC Therapeutics SA (NYSE: ADCT) had its price target lowered by analysts at Guggenheim from $10.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
ADCT
Earnings
- 3/27/25 - Beat
ADCT
Sec Filings
- 3/27/25 - Form ARS
- 3/27/25 - Form 10-K
- 3/27/25 - Form 8-K
- ADCT's page on the SEC website